NEUROSCIENCE TECHNOLOGIES is a research-led company. Our services to companies developing drugs are firmly based on in-house research into the physiology of pain and the pathophysiology of neurological conditions.
Basic Research: development of new experimental models of neuropathic pain, inflammatory pain and migraine; development of new approaches to quantify pain signals within the nervous system.
Clinical Research: studies on new familial neuropathic pain disorders, Fabry's disease and fibromyalgia; pathophysiological mechanisms and psychophysics of pain.
NEUROSCIENCE TECHNOLOGIES participates in several collaborative projects:
- Europain, "Understanding Chronic Pain and Improving its Treatment", Innovative Medicines Initiative, joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
- Dendria, "Innovative Solutions to Accelerate the Development of CNS Drugs", CENIT Programme, Centro para el Desarrollo Tecnológico Industrial (CDTI), Ministerio de Economía y Competitividad, Spanish Government.
- "Characterising the functional significance of abnormal neural afferent patterns in neuropathic pain using intraneural microstimulation", in collaboration with University College London. Industrial CASE studentship, Medical Research Council, UK.
- NEUROPAIN, "Characterisation of subgroups of patients with neuropathic pain". Investigator Initiated Research Grant. Developed by 11 european centres with expertise in Quantitative Sensory Testing (Germany, UK, Spain, Italy, France, Switzerland, Denmark & Finland).